374 related articles for article (PubMed ID: 28522744)
1.
Xi M; Liao Z; Hofstetter WL; Komaki R; Ho L; Lin SH
J Nucl Med; 2017 Nov; 58(11):1756-1763. PubMed ID: 28522744
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of patients with esophageal cancer staged with [¹⁸F]fluorodeoxyglucose positron emission tomography (FDG-PET): can postchemoradiotherapy FDG-PET predict the utility of resection?
Monjazeb AM; Riedlinger G; Aklilu M; Geisinger KR; Mishra G; Isom S; Clark P; Levine EA; Blackstock AW
J Clin Oncol; 2010 Nov; 28(31):4714-21. PubMed ID: 20876421
[TBL] [Abstract][Full Text] [Related]
3. The value of
van Rossum PSN; Fried DV; Zhang L; Hofstetter WL; Ho L; Meijer GJ; Carter BW; Court LE; Lin SH
Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):71-80. PubMed ID: 27511188
[TBL] [Abstract][Full Text] [Related]
4. Change in chemotherapy during concurrent radiation followed by surgery after a suboptimal positron emission tomography response to induction chemotherapy improves outcomes for locally advanced esophageal adenocarcinoma.
Ku GY; Kriplani A; Janjigian YY; Kelsen DP; Rusch VW; Bains M; Chou J; Capanu M; Wu AJ; Goodman KA; Ilson DH
Cancer; 2016 Jul; 122(13):2083-90. PubMed ID: 27152857
[TBL] [Abstract][Full Text] [Related]
5. Early repeated 18F-FDG PET scans during neoadjuvant chemoradiation fail to predict histopathologic response or survival benefit in adenocarcinoma of the esophagus.
Malik V; Lucey JA; Duffy GJ; Wilson L; McNamara L; Keogan M; Gillham C; Reynolds JV
J Nucl Med; 2010 Dec; 51(12):1863-9. PubMed ID: 21078796
[TBL] [Abstract][Full Text] [Related]
6. The predictive value of
Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML
Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034
[TBL] [Abstract][Full Text] [Related]
7. Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with potentially curable esophageal cancer.
van Heijl M; Omloo JM; van Berge Henegouwen MI; Hoekstra OS; Boellaard R; Bossuyt PM; Busch OR; Tilanus HW; Hulshof MC; van der Gaast A; Nieuwenhuijzen GA; Bonenkamp HJ; Plukker JT; Cuesta MA; Ten Kate FJ; Pruim J; van Dekken H; Bergman JJ; Sloof GW; van Lanschot JJ
Ann Surg; 2011 Jan; 253(1):56-63. PubMed ID: 21233607
[TBL] [Abstract][Full Text] [Related]
8. (18)F-fluorodeoxyglucose positron emission tomography immediately after chemoradiotherapy predicts prognosis in patients with locoregional postoperative recurrent esophageal cancer.
Jingu K; Kaneta T; Nemoto K; Takeda K; Ogawa Y; Ariga H; Koto M; Sakayauchi T; Takai Y; Takahashi S; Yamada S
Int J Clin Oncol; 2010 Apr; 15(2):184-90. PubMed ID: 20217449
[TBL] [Abstract][Full Text] [Related]
9. Utility of
Arnett ALH; Merrell KW; Macintosh EM; James SE; Nathan MA; Shen KR; Ravi K; Neben Wittich MA; Haddock MG; Hallemeier CL
J Thorac Oncol; 2017 Jan; 12(1):121-128. PubMed ID: 27569732
[TBL] [Abstract][Full Text] [Related]
10. Value of complete metabolic response by (18)F-fluorodeoxyglucose-positron emission tomography in oesophageal cancer for prediction of pathologic response and survival after preoperative chemoradiotherapy.
Kim MK; Ryu JS; Kim SB; Ahn JH; Kim SY; Park SI; Kim YH; Song HY; Shin JH; Jung HY; Lee GH; Choi KD; Cho KJ; Kim JH
Eur J Cancer; 2007 Jun; 43(9):1385-91. PubMed ID: 17512192
[TBL] [Abstract][Full Text] [Related]
11. Pilot study of serial FLT and FDG-PET/CT imaging to monitor response to neoadjuvant chemoradiotherapy of esophageal adenocarcinoma: correlation with histopathologic response.
Gerbaudo VH; Killoran JH; Kim CK; Hornick JL; Nowak JA; Enzinger PC; Mamon HJ
Ann Nucl Med; 2018 Apr; 32(3):165-174. PubMed ID: 29332233
[TBL] [Abstract][Full Text] [Related]
12. Role of surgical resection in complete responders on FDG-PET after chemoradiotherapy for locally advanced esophageal squamous cell carcinoma.
Jeong Y; Kim JH; Kim SB; Yoon DH; Park SI; Kim YH; Kim HR; Jung HY; Lee GH; Ryu JS
J Surg Oncol; 2014 Apr; 109(5):472-7. PubMed ID: 24301552
[TBL] [Abstract][Full Text] [Related]
13. Role of Repeat 18F-Fluorodeoxyglucose Positron Emission Tomography Examination in Predicting Pathologic Response Following Neoadjuvant Chemoradiotherapy for Esophageal Adenocarcinoma.
Kukar M; Alnaji RM; Jabi F; Platz TA; Attwood K; Nava H; Ben-David K; Mattson D; Salerno K; Malhotra U; Kanehira K; Gannon J; Hochwald SN
JAMA Surg; 2015 Jun; 150(6):555-62. PubMed ID: 25902198
[TBL] [Abstract][Full Text] [Related]
14. The role of qualitative and quantitative analysis of F18-FDG positron emission tomography in predicting pathologic response following chemoradiotherapy in patients with esophageal carcinoma.
Klayton T; Li T; Yu JQ; Keller L; Cheng J; Cohen SJ; Meropol NJ; Scott W; Xu-Welliver M; Konski A
J Gastrointest Cancer; 2012 Dec; 43(4):612-8. PubMed ID: 22777832
[TBL] [Abstract][Full Text] [Related]
15. Randomized Phase II Study of PET Response-Adapted Combined Modality Therapy for Esophageal Cancer: Mature Results of the CALGB 80803 (Alliance) Trial.
Goodman KA; Ou FS; Hall NC; Bekaii-Saab T; Fruth B; Twohy E; Meyers MO; Boffa DJ; Mitchell K; Frankel WL; Niedzwiecki D; Noonan A; Janjigian YY; Thurmes PJ; Venook AP; Meyerhardt JA; O'Reilly EM; Ilson DH
J Clin Oncol; 2021 Sep; 39(25):2803-2815. PubMed ID: 34077237
[TBL] [Abstract][Full Text] [Related]
16. Ineffectiveness of ¹⁸F-fluorodeoxyglucose positron emission tomography in the evaluation of tumor response after completion of neoadjuvant chemoradiation in esophageal cancer.
Piessen G; Petyt G; Duhamel A; Mirabel X; Huglo D; Mariette C
Ann Surg; 2013 Jul; 258(1):66-76. PubMed ID: 23470576
[TBL] [Abstract][Full Text] [Related]
17. The value of ¹⁸F-FDG PET/CT in assessment of metabolic response in esophageal cancer for prediction of histopathological response and survival after preoperative chemoradiotherapy.
Myslivecek M; Neoral C; Vrba R; Vomackova K; Cincibuch J; Formanek R; Koranda P; Zapletalova J
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2012 Jun; 156(2):171-9. PubMed ID: 22660205
[TBL] [Abstract][Full Text] [Related]
18. Predictive value of nodal maximum standardized uptake value of pretreatment [18F]fluorodeoxyglucose positron emission tomography imaging in patients with esophageal cancer.
Yap WK; Chang YC; Tseng CK; Hsieh CH; Chao YK; Su PJ; Hou MM; Yang CK; Pai PC; Lin CR; Hsieh CE; Wu YY; Hung TM
Dis Esophagus; 2017 Aug; 30(8):1-10. PubMed ID: 28575243
[TBL] [Abstract][Full Text] [Related]
19. Correlation of molecular response as measured by 18-FDG positron emission tomography with outcome after chemoradiotherapy in patients with esophageal carcinoma.
Konski AA; Cheng JD; Goldberg M; Li T; Maurer A; Yu JQ; Haluszka O; Scott W; Meropol NJ; Cohen SJ; Freedman G; Weiner LM
Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):358-63. PubMed ID: 17532577
[TBL] [Abstract][Full Text] [Related]
20. The Incremental Value of Subjective and Quantitative Assessment of 18F-FDG PET for the Prediction of Pathologic Complete Response to Preoperative Chemoradiotherapy in Esophageal Cancer.
van Rossum PS; Fried DV; Zhang L; Hofstetter WL; van Vulpen M; Meijer GJ; Court LE; Lin SH
J Nucl Med; 2016 May; 57(5):691-700. PubMed ID: 26795288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
